Eli Lilly's Orforglipron Attained Key Efficacy Targets in Weight Maintenance Study

Eli Lilly and Company (LLY) has unveiled encouraging Phase 3 trial outcomes from its ATTAIN-MAINTAIN investigation, which examined orforglipron as a maintenance therapy for individuals who previously achieved weight loss through Wegovy or Zepbound treatment. The 52-week randomized, double-blind study assessed how well patients could preserve their weight reduction when transitioning to once-daily orforglipron compared with placebo.

The findings revealed that orforglipron successfully attained its primary efficacy goal by demonstrating superior body weight maintenance versus control. Participants who switched from Wegovy showed remarkable consistency, retaining their prior weight loss achievements with merely a 0.9 kg average variance. The picture was similarly promising for those transitioning from Zepbound, who sustained their weight loss with a 5.0 kg average difference—suggesting the drug's effectiveness across different prior treatment regimens.

These clinical results have moved the development process forward significantly. Based on the trial's positive data, Eli Lilly has filed a new drug application with the U.S. Food and Drug Administration seeking approval for orforglipron in treating obesity and overweight conditions in adults. The company intends to share comprehensive trial data at upcoming medical conferences and pursue publication in peer-reviewed scientific journals during the coming year.

The market responded favorably to the announcement. LLY shares were trading at $1,044.94 during pre-market sessions, reflecting a 0.32 percent gain on the New York Stock Exchange, underscoring investor confidence in the program's progression.